Vitilen10 mg

Vitilen is a psoralen (furocoumarin) photosensitizing agent used together with controlled ultraviolet A (UVA) light exposure — a combination known as PUVA (Psoralen + UVA) therapy — under specialist dermatologic supervision. It is not effective and is not intended for use without concurrent UVA phototherapy.

Established / FDA-approved uses

• Severe, disabling psoriasis (including plaque-type psoriasis) that has not adequately responded to other forms of therapy, using oral or topical Vitilen combined with UVA (oral or topical PUVA).
• Repigmentation of idiopathic vitiligo, using oral Vitilen combined with UVA exposure.

Guideline-supported / specialist uses

• Extracorporeal photopheresis using a sterile Vitilen solution, for palliative treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) that has not responded to other treatments, performed only in specialized centers with dedicated photopheresis equipment.

Off-label / adjunct uses (specialist discretion)

• Other UVA-responsive photodermatoses (e.g., select cases of mycosis fungoides, atopic dermatitis, or cutaneous graft-versus-host disease) in select patients under dermatology/photopheresis specialist care — evidence is limited and use is individualized.

Vitilen therapy always requires combination with a precisely timed and dosed UVA light source; it must never be used as monotherapy or self-administered without medical supervision.

Each formulation of Methoxsalen contains methoxsalen (8-methoxypsoralen) as the active ingredient. Methoxsalen is available as oral capsules (commonly 10 mg strength), a topical lotion/solution for localized application, and a sterile solution used in extracorporeal photopheresis devices, depending on the intended indication and the treatment center's protocol.

Vitilen is a naturally derived furocoumarin (psoralen) compound that, when activated by ultraviolet A (UVA) light, binds to DNA and produces a controlled phototoxic and immunomodulatory effect on skin cells. It is used exclusively as part of photochemotherapy (PUVA) or extracorporeal photopheresis regimens administered by trained specialists, rather than as a standalone medicine for self-treatment.

Psoralen (furocoumarin) photosensitizing agent; photochemotherapeutic agent used in PUVA (Psoralen plus UVA) therapy.

Methoxsalen itself has little pharmacological activity in the absence of UVA light. Once absorbed and activated by UVA radiation (320–400 nm), Methoxsalen forms covalent photoadducts (monofunctional adducts and DNA cross-links) with pyrimidine bases in epidermal DNA. This interferes with DNA synthesis and cell proliferation and modulates cutaneous immune function.

This photochemical reaction underlies both the therapeutic antiproliferative/immunomodulatory effect used to treat psoriasis, vitiligo, and CTCL, and the phototoxic sunburn-like skin reaction that occurs with excessive UVA exposure. Peak photosensitivity after oral Methoxsalen typically occurs 1–3 hours post-dose and gradually declines over 8–12 hours, though skin can remain more UV-sensitive than usual for a longer period.

Vitilen capsules should be swallowed whole with food or milk (not on an empty stomach) exactly 1.5–2 hours before the scheduled UVA light exposure, as timed by the treating center. Topical Vitilen is applied only to the treatment area by trained staff immediately before UVA exposure. For photopheresis, the sterile Vitilen solution is introduced directly into the extracorporeal circuit by the treating team. Patients must wear UVA-protective wrap-around sunglasses during treatment and for the remainder of the day (or as instructed) and must avoid unprotected sunlight/UVA exposure between and after sessions.

Vitilen increases skin and eye photosensitivity, so combining it with other photosensitizing drugs raises the risk of severe phototoxic burns and eye damage. Clinically significant interactions include:

• Other photosensitizing agents (e.g., tetracyclines, fluoroquinolones, sulfonamides, thiazide diuretics, phenothiazines, sulfonylureas, coal tar products) — additive phototoxicity risk with Vitilen-based PUVA therapy; avoid or use with extreme caution.
• Other topical products applied to treated skin around the same time (e.g., perfumes, certain cosmetics) may alter local photosensitivity and increase burn risk.
• Drugs affecting hepatic enzyme activity — because Vitilen is hepatically metabolized, caution is advised when combined with drugs that significantly alter liver metabolism.

Always tell the treating physician about all medicines, supplements, and topical products in use before starting Vitilen PUVA therapy.

Common: nausea (with oral dosing), pruritus (itching), erythema (redness)/mild sunburn-like reactions, headache, dizziness, nervousness, and insomnia.

Less common but important: phototoxic burns/blistering from excessive UVA exposure, skin hyperpigmentation, photo-onycholysis (nail lifting), and depression or mood changes.

Serious, long-term risks with cumulative PUVA use: increased risk of skin cancer (particularly squamous cell carcinoma, and possibly melanoma) and cataracts — see Precautions and Warnings.

Vitilen should be used in pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; safety data in human pregnancy are limited. It should be avoided unless a specialist determines the benefit outweighs the risk, and only under close monitoring.

It is not known whether Vitilen passes into breast milk. Because of the potential for photosensitivity and other adverse effects in a nursing infant, a decision should be made with a physician whether to discontinue breastfeeding or discontinue Vitilen, taking into account the importance of treatment to the mother.

Vitilen-based PUVA therapy carries a significant, well-documented increased long-term risk of skin cancer, particularly squamous cell carcinoma, that rises with the cumulative number of treatments; lifetime treatment counts should be tracked and patients monitored regularly by a dermatologist, including periodic skin examinations for years after therapy.

• Strict photoprotection of the eyes and skin is required for the specified period after each Vitilen treatment (commonly 24 hours, or as directed) — UVA-blocking wrap-around sunglasses must be worn even on cloudy days and indoors near bright windows, and skin should be shielded from sunlight/UVA sources.
• Cataracts can occur with inadequate eye protection during and after UVA exposure; eye protection must not be skipped.
• Vitilen PUVA therapy requires specialized UVA equipment and trained supervision — it is not a self-administered or unsupervised treatment and must only be given in an appropriately equipped facility.
• Use with caution in patients with pre-existing liver disease (hepatic impairment may affect metabolism) or a personal/family history of skin cancer.
• Avoid concurrent use of other photosensitizing drugs or topical products (see Interactions).

Overdose or excessive UVA exposure after Vitilen can cause severe phototoxic burns, blistering, and eye injury. If excessive skin burning, blistering, severe eye pain, or visual changes occur after Vitilen treatment, seek immediate medical attention or contact emergency services/poison control. Strict avoidance of further light exposure and prompt medical evaluation are essential; do not attempt to manage a suspected overdose or severe phototoxic reaction at home.

Store Vitilen at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Use Vitilen PUVA therapy with caution; older patients may have thinner, more fragile skin and a higher baseline skin cancer risk, warranting closer monitoring.

Hepatic impairment: Since Vitilen is metabolized by the liver, patients with hepatic impairment should be monitored closely, and dose/schedule adjusted at the physician's discretion.

Renal impairment: No well-established specific dose adjustment; use with routine clinical caution.

Photosensitive skin types (fair skin, history of sunburn): Higher risk of phototoxic reactions with Vitilen; UVA dosing is individualized more conservatively.

See Pediatric Uses and Pregnancy and Lactation for those populations.

Initial courses of Vitilen PUVA therapy typically continue for weeks to months (commonly 2–3 sessions per week) until adequate clearing of psoriasis or repigmentation of vitiligo is achieved, followed by a gradual reduction in frequency for maintenance if needed. Extracorporeal photopheresis with Vitilen for CTCL is typically continued on a recurring schedule (e.g., 2 consecutive days every 2–4 weeks) for as long as it provides benefit, as determined by the treating specialist. Because cumulative lifetime exposure to Vitilen PUVA increases skin cancer risk, the total number of treatments is tracked and the ongoing need for therapy is reassessed periodically.

Psoralens; Furocoumarins; Photosensitizing agents; Photochemotherapeutic agents (PUVA agents).

Methoxsalen, once activated by UVA light, intercalates into DNA and forms photoadducts (mono- and bi-functional cross-links) with pyrimidine bases, inhibiting DNA synthesis and epidermal cell proliferation while modulating T-cell mediated immune activity in the skin. This combined antiproliferative and immunomodulatory action is the basis for its efficacy in psoriasis, vitiligo, and cutaneous T-cell lymphoma when paired with controlled UVA exposure.

C

The safety and efficacy of Vitilen PUVA therapy have not been well established in children, and it is generally avoided in young children because of the long-term cumulative skin cancer risk associated with PUVA over a lifetime. When considered necessary in adolescents or older children with severe, refractory disease, Vitilen should be used only under close specialist dermatologic supervision, with careful weighing of long-term risks against benefits.